Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment

Гудкова, А. Я.; Яковлевна, Гудкова Александра; Streltsova, A. A.; Алексеевна, Стрельцова Анна; Kostareva, Anna; Александровна, Костарева Анна

doi:10.26442/00403660.2019.09.000137

Terapevticheskii arkhiv

2019

DOI: 10.26442/00403660.2019.09.000137

|View full text |Cite

Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment

А. Я. Гудкова

Гудкова Александра Яковлевна²,

A. A. Streltsova

et al.

Abstract: This article discusses recent advances in understanding genetic basis and classification of hypertrophic cardiomyopathy. Here, we review pharmacologic treatment strategies and new developments in disease - specific management of HCM.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 58 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

Габрусенко¹,

Гудкова²,

Козиолова³

et al. 2021

Russ J Cardiol

View full text Add to dashboard Cite

Russian Society of Cardiology (RSC)With the participation: Russian Association of Cardiovascular SurgeonsEndorsed by: Research and Practical Council of the Ministry of Health of the Russian Federation Task Force: Gabrusenko S.A. (Chairman), Gudkova A.Ya.* (Chairman), Koziolova N.A. (Chairman), Alexandrova S.A., Berseneva M.I., Gordeev M.L., Dzemeshkevich S.L., Zaklyazminskaya E.V., Irtyuga O.B., Kaplunova V.Yu., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Saidova M.A., Sanakoev M.K., Stukalova O.V.

show abstract

2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

Габрусенко¹,

Гудкова²,

Козиолова³

et al. 2021

Russ J Cardiol

View full text Add to dashboard Cite

show abstract

Pharmacotherapy for hypertrophic cardiomyopathy

Ignatenko,

Taradin,

Kononenko

2023

jour

View full text Add to dashboard Cite

The presented review concerns modern approaches to drug therapy for hypertrophic cardiomyopathy. General issues of the treatment are touched upon, including lifestyle modification, maintaining adequate hydration and avoiding situations that increase obstruction. The role of traditionally used b-blockers and non-dihydropyridine calcium channel blockers in the treatment of the disease is described. Data on the use of disopyramide are presented, the treatment of which allows reducing the obstruction gradient, ameliorating clinical manifestations and improving diastolic function. Special attention is paid to a new class of drugs — cardiac myosin inhibitors: mavacamten and aficamten. The results of randomized clinical trials regarding to evaluating the efficacy of these drugs are reported. The review presents a modern view of the place of perhexiline, trimetazidine, ranolazine, eleclazine, angiotensin II receptor blockers, combination of sacubitril and valsartan in the therapy of hypertrophic cardiomyopathy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment

Abstract: This article discusses recent advances in understanding genetic basis and classification of hypertrophic cardiomyopathy. Here, we review pharmacologic treatment strategies and new developments in disease - specific management of HCM.

Cited by 2 publications

References 58 publications

2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

Pharmacotherapy for hypertrophic cardiomyopathy

Contact Info

Product

Resources

About